ALXN1720-MG-301试验历史时光轴 Gefurulimab(ALXN 1720) 是第三代 C5 抑制剂,是一种迷你双抗(25kD),只包含了靶向 C5 的抗体重链可变区(VH)和与白蛋白(Albumin)特异性结合的抗体片段。较小的分子量可以带来更好的渗透性,并且与白蛋白的结合能够延长其半衰期。有望成为一款可居家用药的每周 1 次的皮下注射...
Generation and in vitro properties of ALXN1720 a bispecific VHH antibody against complement C5 designed for subcutaneous administration. Poster presentation at the 28th International Complement Virtual Workshop, December 6-10, 2021. (Poster A50). 1 Present address: Takeda Development Center Americas, ...
Gefurulimab (ALXN1720) was developed to provide patients the option of a C5-blocking antibody for subcutaneous self-administration. The heavy-chain variable region antigen-binding fragment (VHH) domain was selected as a building block based on both its size and simplicity, as camelid VHH antibodi...